Paradise Valley, ARIZONA1 Active Studies

Pulmonary Hypertension Clinical Trials in Paradise Valley, ARIZONA

Find 1 actively recruiting pulmonary hypertension clinical trials in Paradise Valley, ARIZONA. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
157
Enrolling

Recruiting Pulmonary Hypertension Studies in Paradise Valley

About Pulmonary Hypertension Clinical Trials in Paradise Valley

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 1 pulmonary hypertension clinical trials recruiting participants in Paradise Valley, ARIZONA. These studies are seeking a combined 157 participants. Research is being sponsored by Uniquity One (UNI). Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in Paradise Valley — FAQ

Are there pulmonary hypertension clinical trials in Paradise Valley?

Yes, there are 1 pulmonary hypertension clinical trials currently recruiting in Paradise Valley, ARIZONA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Paradise Valley?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Paradise Valley research site will contact you about next steps.

Are clinical trials in Paradise Valley free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Paradise Valley studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 1 active trials in Paradise Valley are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated March 2, 2026 from ClinicalTrials.gov